Xarelto gets ACS go-ahead in EU label extensions; Soliris, Viread, MabThera expanded too
This article was originally published in Scrip
Executive Summary
The EMA’s advisory committee, the CHMP, has recommended label extensions for four major products, including new indications for Bayer’s Xarelto (rivaroxaban) and Roche’s MabThera (rituximab).